CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. $1093.HK
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS9
PHASE 3 / 2-35
RECRUITING5
READOUTS ≤12 MONTHS3
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Mitoxantrone hydrochloride liposome injection NCT05717764 |
P3 | Not yet recruiting | Recurrent Metastatic Nasopharyngeal Carcinoma | 500 | 2026-09 |
| SYH2062 NCT07940075 |
P2 | Recruiting | Mild to Moderate Primary Hypertension | 360 | 2027-01-31 |
| SYH2070 NCT07695597 |
P2 | Recruiting | Mixed Hyperlipidemia | 240 | 2027-04-30 |
| SYH2070 injection dose1 NCT07591298 |
P2 | Recruiting | Diagnosed With HoFH | 18 | 2027-09-16 |
| NCT07421284 NCT07421284 |
P3 | Not yet recruiting | Non-familial Hypercholesterolemia and Mixed Hyperlipidemia | 900 | 2027-12-31 |
| SYH2053 injection NCT07421297 |
P3 | Recruiting | Non-familial Hypercholesterolemia and Mixed Hyperlipidemia | 760 | 2027-12-31 |
| SYH2053 Injection NCT07465263 |
P3 | Recruiting | Heterozygous Familial Hypercholesterolemia (HeFH) | 135 | 2028-02-28 |
| SYH2068 Dose 1 NCT07640217 |
P2 | Not yet recruiting | Adult Participants With Elevated Lipoprotein(a) | 120 | 2028-03-30 |
| Aprocitentan tablets(SYH9108) NCT07635914 |
P3 | Not yet recruiting | Resistant Hypertension | 382 | 2029-12-28 |